Industry Insights

  1. Highly Pure L-Carnosine For Cell Therapy Media Applications 2/24/2021

    Cell therapies based on MSCs and T-cells have enabled a series of breakthroughs in patient care. Cell-based, engineered tissues are making significant contributions in the field of regenerative medicine.

  2. CD73: A Team Player Caught In The "AKT" Of Wound Healing And Cell Survival Via MSC Exosomes? 2/24/2025

    CD73, found in MSC exosomes, is a key player in tissue repair. Discover how this protein contributes to cell survival and the intricate process of wound healing.

  3. Addressing Gaps In Cystic Fibrosis Treatment: Fixing Nonsense Mutations 8/8/2023

    Examine how the world’s largest and most diverse collection of novel RGNs and deaminases is increasing the potential for addressing the needs of CF patients with nonsense mutations.

  4. Buyer Beware! Pharmaceutical Equipment Suppliers, Promises, & Delivery 9/30/2020

    Our industry depends on a wide spectrum of equipment suppliers that provide our manufacturing systems, utility systems, and environmental systems. This article raises a number of points to discuss with equipment suppliers and your facility engineers to plan for and assure a successful and compliant installation.

  5. A Launchpad For Scalable Systems In AAV Gene Therapy Manufacturing 3/21/2024

    Identifying a trusted supplier that can address the myriad of challenges that accompany development for AAV-based drugs is critical to securing an asset’s ultimate commercial success.

  6. Is It Time To Say Goodbye To FMEA Risk Priority Number (RPN) Scores? 4/27/2020

    It may be time to consider eliminating the use of the traditional risk priority number (RPN) score and transitioning to the use of action priority (AP) ratings. AP ratings are much simpler to use, do not require a calculation (eliminating the validation of a spreadsheet), and provides a single simple table reference to determine the appropriate level of action.

  7. The Bioanalytical Development Journey 12/14/2023

    Learn how a CDMO with the capability to develop assays to support a wide range of drug substances can support your journey from discovery to clinical manufacturing with reduced cost and time.

  8. Four Questions To Ask Before Implementing Data Quality Software 8/6/2023

    Ensuring high data quality by using data quality software to implement and enforce data quality rules.

  9. CDMO Selection: 7 Steps To Find Your Best Fit 11/11/2024

    Selecting the right CDMO for your project is essential. Here is a practical 7-step process, along with key considerations and pitfalls to avoid along the way.

  10. Continuous Bioprocessing Overtakes Single-Use On List Of Top Technology Trends 10/10/2016

    The desire for innovation in the biopharmaceutical manufacturing industry continues unabated, as companies ramp up their spending on new technologies to improve efficiencies in both upstream and downstream bioprocessing. And while innovation in this industry can be slow to come, the past decade has seen the emergence of several new innovative trends, ranging from the proliferation of single-use devices to growing demand for continuous bioprocessing and modular facilities, according to BioPlan Associates’ 13th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production.